Related Experiment Video
Updated: Sep 24, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
D1/D5 Inverse Agonists Restore Striatal Cholinergic Interneuron Physiology in Dyskinetic Mice
Rodrigo Manuel Paz1, Agostina Mónica Stahl1, Lorena Rela1
1Universidad de Buenos Aires, CONICET, Instituto de Fisiología y Biofísica (IFIBIO) Bernardo Houssay, Grupo de Neurociencia de Sistemas, Buenos Aires, Argentina.
Aberrant striatal cholinergic interneuron (SCIN) activity contributes to Parkinson's disease (PD) motor symptoms. Targeting the D5-cAMP-ERK1/2 pathway in SCINs offers a promising therapeutic strategy for PD and dyskinesia.
Area of Science:
- Neuroscience
- Pharmacology
- Cellular Physiology
Background:
- Advanced Parkinson's disease (PD) presents debilitating motor fluctuations and dyskinesia.
- Striatal cholinergic interneuron (SCIN) dysfunction is critical in PD and dyskinesia.
- Systemic cholinergic drugs can worsen non-motor symptoms, necessitating targeted therapies.
Purpose of the Study:
- Investigate intracellular signaling mechanisms underlying SCIN alterations in a PD mouse model.
- Identify therapeutic targets for severe PD with motor fluctuations and dyskinesia.
Main Methods:
- Ex vivo electrophysiological recordings in a 6-hydroxydopamine mouse model of PD.
- Pharmacological manipulation of intracellular signaling pathways.
- Assessment of SCIN physiology during levodopa treatment and withdrawal.
Main Results:
- Aberrant Kir/leak and Kv1.3 currents in parkinsonian SCINs during "off levodopa" states.
- Acute inhibition of cAMP-ERK1/2 signaling rapidly normalizes SCIN phenotypes.
- D5 receptor inverse agonists (e.g., clozapine) restore SCIN function in dyskinetic mice.
Conclusions:
- A signaling pathway (D5-cAMP-ERK1/2) drives SCIN hyperexcitability in levodopa-treated parkinsonian mice.
- These SCIN changes persist during "off-medication" periods but are reversible.
- Selective targeting of the D5-cAMP-ERK1/2 pathway in SCINs may treat PD and dyskinesia.
More Related Videos
09:44Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Pharmacological Actions